{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:37:23Z","timestamp":1785796643621,"version":"3.56.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Multiple myeloma (MM) is a hematological tumor characterized by the malignant proliferation of plasma cells in bone marrow (BM). Despite the prolonged survival of MM patients, a significant amount of patients relapse or become drug resistant. This underlines the importance of the development and investigation of novel targets to improve MM therapy. Increasing evidences have shed light on the emerging roles of E3 ubiquitin ligases in MM. E3 ubiquitin ligases play an essential role in protein ubiquitination, which is involved in the regulation of protein degradation, protein-protein interactions and signal transduction. In this comprehensive review, we will summarize the current understanding of E3 ubiquitin ligases in MM and their contribution to MM therapy, which could help explore the molecular mechanisms in MM and provide potential therapeutic targets for the treatment of MM.<\/jats:p>","DOI":"10.3389\/fcell.2025.1620097","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:31:45Z","timestamp":1753853505000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Regulatory role of E3 ubiquitin ligases in multiple myeloma: from molecular mechanisms to therapeutic strategies"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoran","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"105443","DOI":"10.1016\/j.phrs.2021.105443","article-title":"TRIM21 - a potential novel therapeutic target in cancer","volume":"165","author":"Alomari","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"101571","DOI":"10.1016\/j.xcrm.2024.101571","article-title":"Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma","volume":"5","author":"Amatangelo","year":"2024","journal-title":"Cell Rep. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/med.21675","article-title":"Skp2 in the ubiquitin-proteasome system: a comprehensive review","volume":"40","author":"Asmamaw","year":"2020","journal-title":"Med. Res. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.3390\/cancers14184492","article-title":"CRL4(CRBN) E3 ligase complex as a therapeutic target in multiple myeloma","volume":"14","author":"Barankiewicz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","article-title":"Spectrum and functional validation of PSMB5 mutations in multiple myeloma","volume":"33","author":"Barrio","year":"2019","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.molcel.2008.05.014","article-title":"cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination","volume":"30","author":"Bertrand","year":"2008","journal-title":"Mol. Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1901346","DOI":"10.1183\/13993003.01346-2019","article-title":"TRIM33 prevents pulmonary fibrosis by impairing TGF-\u03b21 signalling","volume":"55","author":"Boutanquoi","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1182\/blood.2023020731","article-title":"The role of the MDM2\/p53 axis in antitumor immune responses","volume":"143","author":"Brummer","year":"2024","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/ncb2463","article-title":"Fbxw7\u03b1- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma","volume":"14","author":"Busino","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"114536","DOI":"10.1016\/j.celrep.2024.114536","article-title":"SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation","volume":"43","author":"Chang","year":"2024","journal-title":"Cell Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/bloodadvances.2022008241","article-title":"TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy","volume":"7","author":"Chen","year":"2023","journal-title":"Blood Adv."},{"key":"B13","doi-asserted-by":"publisher","first-page":"968755","DOI":"10.3389\/fimmu.2022.968755","article-title":"The emerging roles of TRIM21 in coordinating cancer metabolism, immunity and cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"103905","DOI":"10.1016\/j.cellimm.2019.02.004","article-title":"E3 ubiquitin ligases in B-cell malignancies","volume":"340","author":"Choi","year":"2019","journal-title":"Cell Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.molmed.2024.05.001","article-title":"Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy","volume":"30","author":"Colley","year":"2024","journal-title":"Trends Mol. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1038\/s41388-020-1345-x","article-title":"The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma","volume":"39","author":"Crawford","year":"2020","journal-title":"Oncogene"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/cells11091515","article-title":"The role of E3 ligase Pirh2 in disease","volume":"11","author":"Daks","year":"2022","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.13483","article-title":"Impact of XIAP protein levels on the survival of myeloma cells","volume":"94","author":"Desplanques","year":"2009","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/sj.embor.7400795","article-title":"Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family","volume":"7","author":"Eckelman","year":"2006","journal-title":"EMBO Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41388-024-02977-7","article-title":"O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation","volume":"43","author":"Feng","year":"2024","journal-title":"Oncogene"},{"key":"B22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/ncb2651","article-title":"SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2\/Tti1 degradation and promote survival in multiple myeloma","volume":"15","author":"Fern\u00e1ndez-S\u00e1iz","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","article-title":"New biological therapies for multiple myeloma","volume":"75","author":"Garfall","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.trecan.2024.06.002","article-title":"Targeting cancer stem cells in multiple myeloma","volume":"10","author":"Gunes","year":"2024","journal-title":"Trends Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"675939","DOI":"10.3389\/fcell.2021.675939","article-title":"Targeting RFWD2 as an effective strategy to inhibit cellular proliferation and overcome drug resistance to proteasome inhibitor in multiple myeloma","volume":"9","author":"Guo","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00344-2","article-title":"The changing landscape of relapsed and\/or refractory multiple myeloma (MM): fundamentals and controversies","volume":"10","author":"Hern\u00e1ndez-Rivas","year":"2022","journal-title":"Biomark. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"8212","DOI":"10.1073\/pnas.1101544108","article-title":"Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma","volume":"108","author":"Herquel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41419-022-04629-8","article-title":"NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma","volume":"13","author":"Huang","year":"2022","journal-title":"Cell Death and Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1002\/ijc.32615","article-title":"The NEDD4\u20101 E3 ubiquitin ligase: a potential molecular target for bortezomib sensitivity in multiple myeloma","volume":"146","author":"Huang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"215791","DOI":"10.1016\/j.canlet.2022.215791","article-title":"Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma","volume":"543","author":"Jiang","year":"2022","journal-title":"Cancer Lett."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/1535-7163.MCT-12-0135","article-title":"Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA","volume":"11","author":"Jones","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12929-018-0470-0","article-title":"Ubiquitination by HUWE1 in tumorigenesis and beyond","volume":"25","author":"Kao","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1101\/gad.331231.119","article-title":"Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity","volume":"33","author":"Kim","year":"2019","journal-title":"Genes and Dev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/ni.3559","article-title":"The ubiquitin ligase Huwe1 regulates the maintenance and lymphoid commitment of hematopoietic stem cells","volume":"17","author":"King","year":"2016","journal-title":"Nat. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"32357","DOI":"10.1074\/jbc.M113.459164","article-title":"Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with amplified in liver cancer 1 (ALC1) protein","volume":"288","author":"Kulkarni","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40364-021-00320-w","article-title":"Deubiquitinases in hematological malignancies","volume":"9","author":"Lei","year":"2021","journal-title":"Biomark. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.7150\/ijbs.91284","article-title":"NEDD4 lactylation promotes APAP induced liver injury through Caspase11 dependent non-canonical pyroptosis","volume":"20","author":"Li","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. and Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3324\/haematol.2018.201483","article-title":"Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations","volume":"104","author":"Lim","year":"2019","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41408-024-01117-4","article-title":"Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity","volume":"14","author":"Lind","year":"2024","journal-title":"Blood Cancer J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e103015","DOI":"10.1371\/journal.pone.0103015","article-title":"Inhibition of the MDM2 E3 ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737","volume":"9","author":"Maki","year":"2014","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/leu.2016.258","article-title":"Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes bortezomib resistance in multiple myeloma","volume":"31","author":"Malek","year":"2017","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2010.12.007","article-title":"Ubiquitin makes its mark on immune regulation","volume":"33","author":"Malynn","year":"2010","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J. Med. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1038\/s41598-024-58828-8","article-title":"TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors","volume":"14","author":"McAvera","year":"2024","journal-title":"Sci. Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10875-016-0254-9","article-title":"Autophagy in plasma cell ontogeny and malignancy","volume":"36","author":"Milan","year":"2016","journal-title":"J. Clin. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ajh.20656","article-title":"IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes","volume":"81","author":"Nakagawa","year":"2006","journal-title":"Am. J. Hematol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1158\/1078-0432.CCR-09-1071","article-title":"Interactions of the Hdm2\/p53 and proteasome pathways may enhance the antitumor activity of bortezomib","volume":"15","author":"Ooi","year":"2009","journal-title":"Clin. Cancer Res. Official J. Am. Assoc. For Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.clml.2024.06.004","article-title":"Cereblon E3 ligase modulators mezigdomide and iberdomide in multiple myeloma","volume":"24","author":"Patel","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B53","doi-asserted-by":"publisher","first-page":"189140","DOI":"10.1016\/j.bbcan.2024.189140","article-title":"Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase","volume":"1879","author":"Qi","year":"2024","journal-title":"Biochimica Biophysica Acta. Rev. Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/leu.2014.2","article-title":"Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma","volume":"28","author":"Ramakrishnan","year":"2014","journal-title":"Leukemia"},{"key":"B56","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.critrevonc.2013.02.001","article-title":"Pomalidomide: new immunomodulatory agent with potent antiproliferative effects","volume":"88","author":"Richardson","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjh.13905","article-title":"Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma","volume":"172","author":"Rychak","year":"2016","journal-title":"Br. J. Haematol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4161\/cbt.10.6.12535","article-title":"Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways","volume":"10","author":"Saha","year":"","journal-title":"Cancer Biol. and Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1158\/1535-7163.MCT-10-0471","article-title":"RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses","volume":"9","author":"Saha","year":"","journal-title":"Mol. Cancer Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00018-016-2139-8","article-title":"Functional and pathological relevance of HERC family proteins: a decade later","volume":"73","author":"S\u00e1nchez-Tena","year":"2016","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.18632\/aging.204163","article-title":"E3 ubiquitin ligase RBX1 drives the metastasis of triple negative breast cancer through a FBXO45-TWIST1-dependent degradation mechanism","volume":"14","author":"Shao","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bjh.16213","article-title":"Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure","volume":"188","author":"Siegel","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semcancer.2020.02.001","article-title":"Role of the COP1 protein in cancer development and therapy","volume":"67","author":"Song","year":"2020","journal-title":"Seminars Cancer Biol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1182\/blood.v90.5.1982","article-title":"MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells","volume":"90","author":"Teoh","year":"1997","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3324\/haematol.2024.285636","article-title":"Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond","volume":"110","author":"Teoh","year":"2025","journal-title":"Haematologica"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s41467-019-09446-w","article-title":"Dynamic anticipation by Cdk2\/Cyclin A-bound p27 mediates signal integration in cell cycle regulation","volume":"10","author":"Tsytlonok","year":"2019","journal-title":"Nat. Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"101584","DOI":"10.1016\/j.xcrm.2024.101584","article-title":"Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Van Oekelen","year":"2024","journal-title":"Cell Rep. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"24295","DOI":"10.1074\/jbc.C800128200","article-title":"c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation","volume":"283","author":"Varfolomeev","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12964-024-01699-3","article-title":"Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy","volume":"22","author":"Wang","year":"2024","journal-title":"Cell Commun. Signal. CCS"},{"key":"B71","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.semcancer.2020.03.006","article-title":"NEDD4 E3 ligase: functions and mechanism in human cancer","volume":"67","author":"Wang","year":"2020","journal-title":"Seminars Cancer Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/JCI71602","article-title":"Emerging therapies targeting the ubiquitin proteasome system in cancer","volume":"124","author":"Weathington","year":"2014","journal-title":"J. Clin. Invest"},{"key":"B73","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/1947601910382776","article-title":"Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: the role in cancer and as cancer targets","volume":"1","author":"Wei","year":"2010","journal-title":"Genes and Cancer"},{"key":"B74","first-page":"402","article-title":"Research progress on E3 ubiquitin ligase pellino proteins","volume":"61","author":"Xu","year":"2022","journal-title":"Xiamen Univ. Nat. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"122043","DOI":"10.1016\/j.lfs.2023.122043","article-title":"Regulatory role of E3 ubiquitin ligases in normal B lymphopoiesis and B-cell malignancies","volume":"331","author":"Xu","year":"2023","journal-title":"Life Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","article-title":"ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells","volume":"16","author":"Yamamoto","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1038\/s41467-023-40385-9","article-title":"Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation","volume":"14","author":"Yamanaka","year":"2023","journal-title":"Nat. Commun."},{"key":"B78","doi-asserted-by":"publisher","first-page":"112068","DOI":"10.1016\/j.biopha.2021.112068","article-title":"The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy","volume":"142","author":"Yan","year":"2021","journal-title":"Biomed. and Pharmacother. = Biomedecine and Pharmacother."},{"key":"B79","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s13238-017-0500-9","article-title":"Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-\u03baB signaling pathway","volume":"9","author":"Yang","year":"2018","journal-title":"Protein and Cell"},{"key":"B80","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1073\/pnas.1220271110","article-title":"E3 ligase WWP2 negatively regulates TLR3-mediated innate immune response by targeting TRIF for ubiquitination and degradation","volume":"110","author":"Yang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B81","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/imr.12247","article-title":"Protein ubiquitination in lymphoid malignancies","volume":"263","author":"Yang","year":"2015","journal-title":"Immunol. Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e8412","DOI":"10.1590\/1414-431X20198412","article-title":"Skp2 inhibitor SKPin C1 decreased viability and proliferation of multiple myeloma cells and induced apoptosis","volume":"52","author":"Yang","year":"2019","journal-title":"Braz. J. Med. Biol. Res. = Revista Brasileira de Pesquisas Medicas E Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"101257","DOI":"10.1016\/j.mam.2024.101257","article-title":"E3 ubiquitin ligase WWP2 as a promising therapeutic target for diverse human diseases","volume":"96","author":"You","year":"2024","journal-title":"Mol. Aspects Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.celrep.2014.03.045","article-title":"Impeded Nedd4-1-mediated ras degradation underlies Ras-driven tumorigenesis","volume":"7","author":"Zeng","year":"2014","journal-title":"Cell Rep."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/carcin\/bgab086","article-title":"DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination","volume":"42","author":"Zhang","year":"2021","journal-title":"Carcinogenesis"},{"key":"B86","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10020-023-00628-3","article-title":"The role of NEDD4 related HECT-type E3 ubiquitin ligases in defective autophagy in cancer cells: molecular mechanisms and therapeutic perspectives","volume":"29","author":"Zhang","year":"2023","journal-title":"Mol. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.7150\/ijbs.48437","article-title":"E3 ubiquitin ligase NEDD4 family-regulatory network in cardiovascular disease","volume":"16","author":"Zhang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"104675","DOI":"10.1016\/j.jbc.2023.104675","article-title":"The ubiquitin ligase HERC4 suppresses MafA transcriptional activity triggered by GSK3\u03b2 in myeloma by atypical K63-linked polyubiquitination","volume":"299","author":"Zhang","year":"2023","journal-title":"J. Biol. Chem."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1182\/blood-2015-07-658203","article-title":"The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-019-0713-x","article-title":"The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo","volume":"12","author":"Zhou","year":"2019","journal-title":"J. Hematol. and Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/cr.2013.44","article-title":"Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases","volume":"23","author":"Zhou","year":"2013","journal-title":"Cell Res."},{"key":"B92","volume-title":"Ubiquitination in cancer: mechanisms and therapeutic opportunities","author":"Zhu","year":"2025"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1620097\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:31:47Z","timestamp":1753853507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1620097\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":92,"alternative-id":["10.3389\/fcell.2025.1620097"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2025.1620097","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"1620097"}}